Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Price Website

Douglas K. Price, Ph.D.

Selected Publications

1)  Roth JE, Peer CJ, Price DK, Figg WD.
The androgen receptor transcriptional program in castration-resistant prostate cancer: cell lines vs. tissue samples.
Cancer Biol. Ther. 15: 16-8, 2014.
2)  Gao R, Reece KM, Sissung T, Fu SH, Venzon DJ, Reed E, Spencer SD, Price DK, Figg WD.
Are race-specific ERCC1 haplotypes in melanoma cases versus controls related to the predictive and prognostic value of ERCC1 N118N?.
BMJ Open. 3, 2013.
3)  Hall C, Troutman SM, Price DK, Figg WD, Kang MH.
Bcl-2 family of proteins as therapeutic targets in genitourinary neoplasms.
Clin Genitourin Cancer. 11: 10-9, 2013.
4)  Fernández EV, Price DK, Figg WD.
Prostate cancer progression attributed to autonomic nerve development: potential for therapeutic prevention of localized and metastatic disease.
Cancer Biol. Ther. 14: 1005-6, 2013.
5)  Johnson LM, Price DK, Figg WD.
Treatment-induced secretion of WNT16B promotes tumor growth and acquired resistance to chemotherapy: implications for potential use of inhibitors in cancer treatment.
Cancer Biol. Ther. 14: 90-1, 2013.
6)  Troutman SM, Sissung TM, Cropp CD, Venzon DJ, Spencer SD, Adesunloye BA, Huang X, Karzai FH, Price DK, Figg WD.
Racial disparities in the association between variants on 8q24 and prostate cancer: a systematic review and meta-analysis.
Oncologist. 17: 312-20, 2012.
7)  Richardson ED, Price DK, Figg WD.
Significant addition to treatment options for bone metastasis in prostate cancer.
Cancer Biol. Ther. 13: 69-70, 2012.
8)  Sissung TM, Danesi R, Kirkland CT, Baum CE, Ockers SB, Stein EV, Venzon D, Price DK, Figg WD.
Estrogen receptor a and aromatase polymorphisms affect risk, prognosis, and therapeutic outcome in men with castration-resistant prostate cancer treated with docetaxel-based therapy.
J. Clin. Endocrinol. Metab. 96: E368-72, 2011.
9)  Pressler H, Sissung TM, Venzon D, Price DK, Figg WD.
Expression of OATP family members in hormone-related cancers: potential markers of progression.
PLoS ONE. 6: e20372, 2011.
10)  Sissung TM, Gardner ER, Piekarz RL, Howden R, Chen X, Woo S, Franke R, Clark JA, Miller-DeGraff L, Steinberg SM, Venzon D, Liewehr D, Kleeberger SR, Bates SE, Price DK, Rosing DR, Cabell C, Sparreboom A, Figg WD.
Impact of ABCB1 allelic variants on QTc interval prolongation.
Clin. Cancer Res. 17: 937-46, 2011.
Click Here to View Expanded Bibliography.

This page was last updated on 3/25/2014.